Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 1
2000 2
2001 3
2002 3
2003 4
2004 5
2005 2
2007 5
2008 4
2009 3
2010 8
2011 4
2012 2
2013 5
2014 6
2015 9
2016 4
2017 10
2018 5
2019 5
2020 4
2021 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 32161494

92 results

Results by year

Filters applied: . Clear all
Page 1
Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, Nomura T, Morimoto T, Yamamoto D, Tsubota Y, Kobayashi T, Uchiyama K. Tanaka S, et al. Clin Breast Cancer. 2015 Jun;15(3):191-6. doi: 10.1016/j.clbc.2014.12.003. Epub 2014 Dec 24. Clin Breast Cancer. 2015. PMID: 25579459 Clinical Trial.
Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y. Watanabe T, et al. Cancer. 2017 Mar 1;123(5):759-768. doi: 10.1002/cncr.30421. Epub 2017 Jan 12. Cancer. 2017. PMID: 28081304 Free PMC article. Clinical Trial.
Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Futamura M, Nagao Y, Ishihara K, Takeuchi M, Nakada T, Kawaguchi Y, Asano M, Kumazawa I, Shiroko T, Morimitsu K, Mori R, Nawa M, Shimokawa T, Yoshida K. Futamura M, et al. Breast Cancer. 2017 Jul;24(4):615-623. doi: 10.1007/s12282-016-0748-6. Epub 2017 Jan 3. Breast Cancer. 2017. PMID: 28050738 Free PMC article. Clinical Trial.
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H, Ueda S, Saeki T, Shigekawa T, Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T, Matsuura K, Yamane T, Kuji I, Hasebe T, Osaki A. Shimada H, et al. Jpn J Clin Oncol. 2015 Jul;45(7):642-9. doi: 10.1093/jjco/hyv055. Epub 2015 May 19. Jpn J Clin Oncol. 2015. PMID: 25989989 Clinical Trial.
Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G. Frasci G, et al. Breast Cancer Res Treat. 1999 Aug;56(3):239-52. doi: 10.1023/a:1006263226099. Breast Cancer Res Treat. 1999. PMID: 10573115 Clinical Trial.
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y, Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y. Shirakawa T, et al. Cancer Chemother Pharmacol. 2014 Dec;74(6):1207-15. doi: 10.1007/s00280-014-2597-3. Epub 2014 Sep 30. Cancer Chemother Pharmacol. 2014. PMID: 25267597
92 results